ACUT
What one share of Accustem Sciences holds
Pharmaceutical Preparations
We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who are diagnosed with cancer each year.
Accustem Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.10 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.07 | — | — | — | $0.07 |
| 2022 | — | −$0.34 | $0.00 | −$0.16 | — | −$0.01 |
| 2023 | — | −$0.18 | — | −$0.14 | — | −$0.19 |
| 2024 | — | −$0.13 | — | −$0.06 | — | −$0.27 |
| 2025 | — | −$0.12 | — | −$0.06 | — | −$0.21 |